Disclosure Of Entity's Operating Segments [Text Block]

ABIONYX Pharma - Filing #2810725

Concept	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31
Disclosure of entity's operating segments [text block]	—	XXXIII.	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of operating segments [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of operating segments [abstract]
Disclosure of operating segments [line items]
Revenue	—	4 640 EUR	—	—	—	—	—	—	—	—	—	5 252 EUR	—	—	—	—
Tax expense (income)	—	0 EUR	—	—	—	—	—	—	—	—	—	0 EUR	—	—	—	—
Profit (loss)	0 EUR	3 518 EUR	0 EUR	0 EUR	—	3 518 EUR	0 EUR	0 EUR	—	0 EUR	0 EUR	4 206 EUR	0 EUR	0 EUR	4 206 EUR	0 EUR
Assets	—	—	—	—	14 834 EUR	—	—	—	15 823 EUR	—	—	—	—	—	—	—
Cash flows from (used in) operating activities	—	3 698 EUR	—	—	—	—	—	—	—	—	—	3 359 EUR	—	—	—	—
Cash flows from (used in) investing activities	—	130,000 EUR	—	—	—	—	—	—	—	—	—	175,000 EUR	—	—	—	—
Cash flows from (used in) financing activities	—	3 886 EUR	—	—	—	—	—	—	—	—	—	194,000 EUR	—	—	—	—
Disclosure of products and services [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of products and services [abstract]
Disclosure of products and services [line items]
Disclosure of geographical areas [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of geographical areas [abstract]
Disclosure of geographical areas [line items]
Disclosure of major customers [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of major customers [abstract]
Disclosure of major customers [line items]